Supplementary materials for: The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials

Table I. Trial Registration
Table II: Efficacy Outcomes Scales
Table III: Proportion of Patients Achieving EASI 75 During Treatment in the Escape Arm
Table IV. Overview of Adverse Events
Table V. Rescue Therapy Usage from Week 16 to Week 52
Figure 1. Study Design for ADvocate1 and ADvocate2
Figure 2. ADvocate1 and ADvocate2 Pooled Patient Disposition
Figure 3. Time Course of Response (Supportive Analysis)